NewsMV
Milwaukee law firm Ademi LLP has opened an investigation into NextCure (NASDAQ: NXTC), examining whether the biotech's recently announced transaction with Avere Therapeutics delivers a fair price to public shareholders.
The probe targets possible breaches of fiduciary duty and other violations of law tied to the deal. The next confirmable step: any formal legal action or additional filing that follows from the inquiry.
Scope of the investigation Ademi LLP's inquiry focuses on fairness to NextCure's public shareholder base, specifically whether the transaction terms with Avere Therapeutics satisfy the board's obligation to stockholders.
No deal price, premium, or other financial terms appeared in the announcement.
Keep reading